Q2 2025 Harrow Inc Earnings Call Transcript
Key Points
- Harrow Inc (HROW) reported a 30% increase in total revenue for the second quarter of 2025 compared to the same period in 2024, reaching $63.7 million.
- The company has a strong commercial infrastructure with over 59 prescription products, addressing both front and back of the eye diseases.
- Harrow Inc (HROW) announced strategic acquisitions, including the US rights to BYQLOVI and Samsung's ophthalmic biosimilars pipeline, enhancing its product portfolio.
- The VEVYE Access for All initiative led to a 66% growth in prescription volumes quarter-over-quarter, indicating strong market penetration.
- Harrow Inc (HROW) has established a strategic alliance with Apollo Care, expanding its distribution network and improving pharmacy access and insurance coverage for patients.
- VEVYE experienced a 13% decrease in revenue from the first quarter of 2025 due to a normalization in average selling price.
- The company needs to generate approximately $169 million in revenue in the second half of the year to meet its 2025 guidance, posing a significant challenge.
- Harrow Inc (HROW) faces risks and uncertainties related to the FDA approval of certain drug candidates and the ability to make commercially available its FDA-approved products.
- The company has not yet fully invested in expanding its sales organization, which may limit its ability to capture new markets and prescribers.
- There is a need for improved supply chain management to ensure sufficient safety stock for VEVYE, which could impact future growth if not addressed.
Good morning and welcome to Harrow's second-quarter 2025 earnings conference call. My name is Shannon and I will be your operator for today's call. (Operator Instructions)
As a reminder this conference is being recorded.
I would now like to turn the conference over to Mike Biega, Vice President of Investor Relations and Communications for Harrow.
Thank you, operator. Good morning, and welcome to Harrow's second-quarter 2025 earnings conference call. My name is Mike Biega, and I'm excited to be introducing today's call, having joined Harrow as Vice President of Investor Relations and Communications in June. It's a pleasure to be part of the Harrow family and to speak with all of you this morning.
Before we begin today, I would like to highlight a few new items for our quarterly report. We will be presenting slides during the webcast today. If you have registered and joined through the live conference call link, I would highly recommend that you also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
